Abstract 545P
Background
Immune checkpoint inhibitors (ICI) are standard of care in advanced non-small cell lung cancer (NSCLC) without driver mutations. A small proportion of patients (pts) treated with ICIs will achieve durable responses. We describe outcomes of a real-world cohort of pts who completed two years of pembrolizumab (pembro).
Methods
Clinical data of pts who completed 35 cycles of first-line pembro for NSCLC (or 30-34 cycles with reason for cessation other than progression) was collected retrospectively from sites across Australia via the AUstralian Registry and biObank of thoRacic cAncers (AURORA). Primary endpoints were progression rate post pembro completion and progression free survival (PFS). Local treatment of oligoprogressive disease during pembro was included. Analyses were performed using R.
Results
71 pts from six centres with a median age of 66.0 yrs, 49% male & 90% ECOG≤1 were identified. Pts were Caucasian (82%) or Asian (16%); past (69%) or current (25%) smokers with a mean 37 pack year history. Histology comprised 73% adenocarcinoma, 16% squamous. 18 pts (25%) had brain mets at diagnosis, 16 treated (8 resected, 8 RT). Median PD-L1 tumour proportion score (TPS) was 68%; 12 pts (17%) PD-L1 negative, 43 pts (61%) TPS≥50%. No pts had ALK/ROS/EGFR mutations; 29/49 tested (60%) had K-Ras mutations. Median follow up from pembro start was 38.7 months (24.5 – 65.6). Table: 545P
Total population (n=71) | |||
Pembro | 39 (55%) | Median time on pembro | 24.2 mo |
Pembro + chemo | 32 (45%) | (20.0-35.3) | |
Objective Response Rate (ORR) | 78.6% | 76.9% | |
CR | 20 (29%) | ORR pembro | 80.6% |
PR | 35 (50%) | ORR pembro+chemo | p=0.86 |
Median PFS | 46.1 mo (95%CI 39.5-NR) | PFS in PD-L1≥1%PFS in PD-L1 neg | NR (46.1-NR)28.1 mo (16.3-NR)p=0.013 |
Oligoprogression during pembro | |||
Total | 17 (24%) | ||
Locoregional | 8 | PFS oligo subgroup | 12.0 mo (9.4-18.9) |
Brain | 7 | PFS2 | 23.1 mo (20.2-NR) |
Progression post pembro | |||
Total | 20 (28%) | Median time to progression | 3.3 mo (1.0-26.3) |
Locoregional | 11 | ||
Brain | 3 | ||
Bone | 5 | ||
PD-L1≥1% | 13 | Pts with CR | 2 |
PD-L1 neg | 6 (OR 3.46, p=0.06) | Pts without CR | 18 (OR 5.06, p=0.04) |
Brain mets at diagnosis (n=18) | |||
CNS progression | 6 (33%) |
Conclusions
Pts completing two years of pembro for NSCLC in Australia had high rates of K-Ras mutation and PD-L1 expression; a significant proportion had brain metastases and treated oligoprogression. Progression rate post pembro was higher in PD-L1-negative pts and in those without complete response.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
AURORA (AUstralian Registry and biObank of thoRacic cAncers) national database. Each participating hospital in various sites throughout Australia had ethics approval to contribute to the AURORA database via their local ethics committee.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
227P - Proteomic analysis of urothelial lesions reveals novel diagnostic biomarkers to distinguish pathologic pitfalls and protein-protein interactions
Presenter: Changlim Hyun
Session: Poster Display
Resources:
Abstract
228P - Real-world data on dose adjustment of cabozantinib in advanced renal cell carcinoma
Presenter: Hemavathi Baskarane
Session: Poster Display
Resources:
Abstract
229P - The application of diffusion kurtosis imaging in predicting muscle invasion of bladder cancer: A comparison with conventional DWI
Presenter: Shuai Jiang
Session: Poster Display
Resources:
Abstract
230P - Oncological outcomes between partial cystectomy and radical cystectomy in solitary muscle invasive bladder cancer with downgraded T stage
Presenter: Ming Wei Hsu
Session: Poster Display
Resources:
Abstract
231P - BMI-predicted progression-free survival after pembrolizumab therapy for urothelial cancer: Asian version of BMI classification is suitable for Asian patients
Presenter: mirii harada
Session: Poster Display
Resources:
Abstract
232P - The immunosuppressive features of the 20S Proteasome β-subunit gene family in von Hippel-Lindau (VHL)-mutated clear cell renal cell carcinoma (ccRCC): A TCGA-based bioinformatics study
Presenter: Saja Alzghoul
Session: Poster Display
Resources:
Abstract
233P - The crosstalk between PBRM1 loss and tumor immune microenvironment (TIME) of clear cell renal cell carcinoma (ccRCC): A possible interconnection to immunotherapy response
Presenter: Ahmed Al Sharie
Session: Poster Display
Resources:
Abstract
235P - Do FGFR2 and 3 proteins have a role in the prognosis of urothelial bladder carcinoma?
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
236P - The effects of chemotherapy on body composition in patients with advanced urothelial carcinoma
Presenter: KOSUKE KITAMURA
Session: Poster Display
Resources:
Abstract
237P - Real-world analysis of adjuvant nivolumab in resected urothelial cancer: A single institute study in Taiwanese patients
Presenter: Mu-Hsin Chang
Session: Poster Display
Resources:
Abstract